Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) Director Nancy Thornberry sold 1,000 shares of the firm's stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $547.86, for a total value of $547,860.00. Following the completion of the sale, the director directly owned 1,109 shares in the company, valued at $607,576.74. The trade was a 47.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vertex Pharmaceuticals Trading Up 0.4%
NASDAQ:VRTX traded up $2.25 during mid-day trading on Wednesday, reaching $536.45. 1,284,080 shares of the company's stock traded hands, compared to its average volume of 1,392,333. The company has a 50 day moving average price of $522.31 and a 200-day moving average price of $484.43. The firm has a market capitalization of $136.01 billion, a price-to-earnings ratio of 34.52, a PEG ratio of 2.85 and a beta of 0.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 1.89. Vertex Pharmaceuticals Incorporated has a 12-month low of $412.27 and a 12-month high of $568.67.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts' consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The business had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the prior year, the business posted $4.80 earnings per share. Vertex Pharmaceuticals's quarterly revenue was up 11.8% compared to the same quarter last year. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current year.
Institutional Investors Weigh In On Vertex Pharmaceuticals
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Coastal Bridge Advisors LLC purchased a new stake in Vertex Pharmaceuticals in the third quarter valued at $706,000. Zacks Investment Management raised its stake in shares of Vertex Pharmaceuticals by 2.2% during the 3rd quarter. Zacks Investment Management now owns 56,258 shares of the pharmaceutical company's stock valued at $29,413,000 after buying an additional 1,206 shares during the last quarter. Integrated Wealth Concepts LLC lifted its holdings in shares of Vertex Pharmaceuticals by 6.2% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 6,285 shares of the pharmaceutical company's stock valued at $3,286,000 after buying an additional 368 shares during the period. Groupama Asset Managment lifted its holdings in shares of Vertex Pharmaceuticals by 14.3% in the 3rd quarter. Groupama Asset Managment now owns 215,115 shares of the pharmaceutical company's stock valued at $112,464,000 after buying an additional 26,959 shares during the period. Finally, EWA LLC lifted its holdings in shares of Vertex Pharmaceuticals by 3.9% in the 3rd quarter. EWA LLC now owns 511 shares of the pharmaceutical company's stock valued at $267,000 after buying an additional 19 shares during the period. 90.96% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research firms recently weighed in on VRTX. Weiss Ratings cut shares of Vertex Pharmaceuticals from a "buy (b)" rating to a "buy (b-)" rating in a report on Monday, November 9th. Canaccord Genuity Group upped their price objective on shares of Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a "hold" rating in a report on Tuesday, August 4th. Sanford C. Bernstein raised shares of Vertex Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, July 29th. Royal Bank Of Canada lifted their target price on shares of Vertex Pharmaceuticals from $576.00 to $600.00 and gave the company an "outperform" rating in a research note on Tuesday, November 3rd. Finally, Morgan Stanley reduced their price target on shares of Vertex Pharmaceuticals from $665.00 to $660.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $596.44.
View Our Latest Stock Analysis on VRTX
About Vertex Pharmaceuticals
(
Get Free Report)
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex's CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.